US EditionPublished • loading... • Updated
Ozempic Approved In India: A New Option For Type-2 Diabetes, But At What Cost?
Summary by newsmobile.in
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Ozempic Approved In India: A New Option For Type-2 Diabetes, But At What Cost?
India’s drug regulator has approved Ozempic (semaglutide), a once-weekly injection developed by Danish pharmaceutical giant Novo Nordisk, for the treatment of adults with type 2 diabetes. The move is expected to bring new hope to millions of Indians living with the condition, though questions about pricing, accessibility, and long-term safety remain. From FDA Nod to Indian Market Ozempic first received the US FDA’s approval in 2017 as a treatmen…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
